MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Troglitazone
CAS No. : 97322-87-7
MCE 国际站：Troglitazone
产品活性：Troglitazone 是口服有效的 PPARγ 激动剂，对人和鼠 PPARγ的 EC50 值分别为 550 nM 和 780 nM。Troglitazone 具有抗癌活性，并能预防和抑制 2 型糖尿病发展。
研究领域：Cell Cycle/DNA Damage | Vitamin D Related/Nuclear Receptor | Metabolic Enzyme/Protease | Autophagy | Apoptosis
作用靶点：PPAR | Autophagy | Apoptosis | Ferroptosis
In Vitro: Troglitazone (2-200 μM, 24 h) is cytotoxic to the pancreatic cancer cell lines (MIA Paca2 and PANC-1 cells), with IC50s of 49.9±1.2 and 51.3±5.3 μM, respectively.
Troglitazone (50 μM, 24 h) increases chromatin condensation in MIA Paca2 and PANC-1 cells, enhances the activity of caspase-3 and decreases Bcl-2 expression.
Troglitazone (0-4 μM, 12 h) sensitizes TRAIL-mediated apoptosis in human lung adenocarcinoma cells (A549, HCC-15 and Calu-3).
Troglitazone (0-4 μM, 12 h) induces autophagy and sensitized apoptosis mediated by TRAIL in A549 cells.
In Vivo: Troglitazone (200 mg/kg, p.o., every day for 5 weeks) shows inhibitory effects on the growth of tumor in the MIA Paca2 xenograft model.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-diabetic Compound Library | Ferroptosis Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Obesity Compound Library | Transcription Factor-Targeted Library | Lipid Metabolism Compound Library | Antidepressant Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Nuclear Receptor Compound Library | Osteogenesis Compound Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Withdrawn Drug Compound Library | Off-patent Drug Library | Mitochondrial Protection Compound Library | Metabolic Enzyme Compound Library | Mitochondrial Toxicity Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | Bioactive Compound Library Max | MG-132 | Ferrostatin-1 | Erastin | Cisplatin | Cycloheximide | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | RSL3 | Y-27632 | Paclitaxel | Z-VAD-FMK | LY294002 | 2-Deoxy-D-glucose | Angiotensin II human | Acetylcysteine | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Oxaliplatin | Deferoxamine mesylate | Sorafenib | Trametinib | ML385 | Necrostatin-1 | Retinoic acid | Gemcitabine | Temozolomide
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
